Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.

Kim SH, Abbasi F, Nachmanoff C, Stefanakis K, Kumar A, Kalra B, Savjani G, Mantzoros CS

Diabetes, obesity & metabolism19 Nov 2020Cited by 22 (Europe PMC)

PMID33140542PMCIDPMC7856054DOI10.1111/dom.14242PepBankPUB-33140542

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with prediabetes, liraglutide decreased body weight by a mean of 3.6% versus placebo over 14 weeks.
In plain wordsIn overweight adults with prediabetes, liraglutide led to more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 35
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
body weight change
−3.6%
liraglutide vs placebo
Source sentences
Summary
Participants on liraglutide versus placebo had significantly (P ≤ .004) decreased weight (mean -3.6%, 95% CI [-5.2% to -2.1%]), SSPG (-32% [-43% to -22%]) and glucose AUC (-7.0% [-11.5% to -2.5%]) and increased ISR AUC (30% [16% to 44%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054201
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with prediabetes, liraglutide decreased steady-state plasma glucose, a measure of insulin resistance, versus placebo.
In plain wordsIn overweight adults with prediabetes, liraglutide reduced insulin resistance more than placebo.
Peptide
Liraglutide
Outcome
DecreaseSteady-state plasma glucose (insulin resistance)
Study
n = 35
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
SSPG change
−32%
liraglutide vs placebo
Source sentences
Summary
Participants on liraglutide versus placebo had significantly (P ≤ .004) decreased weight (mean -3.6%, 95% CI [-5.2% to -2.1%]), SSPG (-32% [-43% to -22%]) and glucose AUC (-7.0% [-11.5% to -2.5%]) and increased ISR AUC (30% [16% to 44%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054202
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with prediabetes, liraglutide decreased glucose AUC during the mixed meal test versus placebo.
In plain wordsIn overweight adults with prediabetes, liraglutide lowered blood glucose after a meal more than placebo.
Peptide
Liraglutide
Outcome
DecreaseGlucose AUC during mixed meal tolerance test
Study
n = 35
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
glucose AUC change
−7%
liraglutide vs placebo
Source sentences
Summary
Participants on liraglutide versus placebo had significantly (P ≤ .004) decreased weight (mean -3.6%, 95% CI [-5.2% to -2.1%]), SSPG (-32% [-43% to -22%]) and glucose AUC (-7.0% [-11.5% to -2.5%]) and increased ISR AUC (30% [16% to 44%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054203
04HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults with prediabetes, liraglutide increased insulin secretion rate AUC versus placebo.
In plain wordsIn overweight adults with prediabetes, liraglutide increased insulin secretion more than placebo.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion rate AUC
Study
n = 35
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
ISR AUC change
30%
liraglutide vs placebo
Source sentences
Summary
Participants on liraglutide versus placebo had significantly (P ≤ .004) decreased weight (mean -3.6%, 95% CI [-5.2% to -2.1%]), SSPG (-32% [-43% to -22%]) and glucose AUC (-7.0% [-11.5% to -2.5%]) and increased ISR AUC (30% [16% to 44%]).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054204
05HumanRandomized controlled trialMechanism
In overweight or obese adults with prediabetes on liraglutide, higher circulating liraglutide (GLP-1A) AUC was linearly associated with a larger percent weight decrease.
In plain wordsIn overweight adults with prediabetes on liraglutide, higher liraglutide blood levels were linked to more weight loss.
Peptide
Liraglutide
Outcome
Not applicableAssociation of exogenous GLP-1A AUC with weight decrease
Study
n = 16
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
correlation
−0.54 r
GLP-1A AUC vs % weight decrease
Source sentences
Summary
GLP-1A AUC at study end was significantly (P ≤ .04) linearly associated with % decrease in weight (r = -0.54) and SSPG (r = -0.59) and increase in ISR AUC (r = 0.51) in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054205
06HumanRandomized controlled trialMechanism
In overweight or obese adults with prediabetes on liraglutide, higher circulating liraglutide (GLP-1A) AUC was linearly associated with a larger decrease in steady-state plasma glucose.
In plain wordsIn overweight adults with prediabetes on liraglutide, higher liraglutide blood levels were linked to less insulin resistance.
Peptide
Liraglutide
Outcome
Not applicableAssociation of exogenous GLP-1A AUC with steady-state plasma glucose decrease
Study
n = 16
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
correlation
−0.59 r
GLP-1A AUC vs SSPG
Source sentences
Summary
GLP-1A AUC at study end was significantly (P ≤ .04) linearly associated with % decrease in weight (r = -0.54) and SSPG (r = -0.59) and increase in ISR AUC (r = 0.51) in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054206
07HumanRandomized controlled trialMechanism
In overweight or obese adults with prediabetes on liraglutide, higher circulating liraglutide (GLP-1A) AUC was linearly associated with a larger increase in insulin secretion rate AUC.
In plain wordsIn overweight adults with prediabetes on liraglutide, higher liraglutide blood levels were linked to more insulin secretion.
Peptide
Liraglutide
Outcome
Not applicableAssociation of exogenous GLP-1A AUC with insulin secretion rate AUC increase
Study
n = 16
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
correlation
0.51 r
GLP-1A AUC vs ISR AUC
Source sentences
Summary
GLP-1A AUC at study end was significantly (P ≤ .04) linearly associated with % decrease in weight (r = -0.54) and SSPG (r = -0.59) and increase in ISR AUC (r = 0.51) in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054207
08HumanRandomized controlled trialPharmacokinetics
In overweight or obese adults with prediabetes, liraglutide treatment significantly increased exogenous GLP-1A (liraglutide) AUC compared with baseline.
In plain wordsIn overweight adults with prediabetes, liraglutide treatment raised measured liraglutide levels after a meal, compared with baseline.
Peptide
Liraglutide
Outcome
IncreaseExogenous GLP-1A AUC during mixed meal test
Study
n = 16
Comparator
Baseline
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
exogenous GLP-1A AUC
310 pg/mL x 8 hours
liraglutide, week 14 (median)
exogenous GLP-1A AUC
262 pg/mL x 8 hours
baseline (median)
Source sentences
Summary
Treatment with liraglutide significantly (P ≤ .005) increased exogenous GLP-1A AUC (median 310 vs. 262 pg/mL × 8 hours at baseline but decreased endogenous GLP-1E AUC [13.1 vs. 24.2 pmol/L × 8 hours at baseline]), as well as the five other PGDPs.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054208
09HumanRandomized controlled trialMechanism
In overweight or obese adults with prediabetes, liraglutide treatment significantly decreased the body's own GLP-1 (GLP-1E) AUC compared with baseline.
In plain wordsIn overweight adults with prediabetes, liraglutide treatment lowered the body's own GLP-1 levels, compared with baseline.
Peptide
Liraglutide
Outcome
DecreaseEndogenous GLP-1 (GLP-1E) AUC
Study
n = 16
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
endogenous GLP-1E AUC
13.1 pmol/L x 8 hours
liraglutide, week 14
endogenous GLP-1E AUC
24.2 pmol/L x 8 hours
baseline
Source sentences
Summary
Treatment with liraglutide significantly (P ≤ .005) increased exogenous GLP-1A AUC (median 310 vs. 262 pg/mL × 8 hours at baseline but decreased endogenous GLP-1E AUC [13.1 vs. 24.2 pmol/L × 8 hours at baseline]), as well as the five other PGDPs.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054209
10HumanRandomized controlled trialMechanism
In overweight or obese adults with prediabetes, liraglutide treatment significantly decreased the AUC of five other proglucagon-derived peptides compared with baseline.
In plain wordsIn overweight adults with prediabetes, liraglutide treatment lowered levels of five related gut and pancreas hormones, compared with baseline.
Peptide
Liraglutide
Outcome
DecreaseFive other proglucagon-derived peptides AUC
Study
n = 16
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Treatment with liraglutide significantly (P ≤ .005) increased exogenous GLP-1A AUC (median 310 vs. 262 pg/mL × 8 hours at baseline but decreased endogenous GLP-1E AUC [13.1 vs. 24.2 pmol/L × 8 hours at baseline]), as well as the five other PGDPs.
2 context sentences(design, population, supporting numbers)
Summary · context
Adults who were overweight/obese (body mass index 27-40 kg/m² ) with prediabetes were randomized to liraglutide (1.8 mg/day) versus placebo for 14 weeks.
Summary · context
We used specific assays to measure exogenous (liraglutide, GLP-1 agonist [GLP-1A]) and endogenous (GLP-1E) GLP-1, alongside five other PGDP concentrations during a mixed meal tolerance test (MMTT) completed at baseline and at week 14 (liraglutide, n = 16; placebo, n = 19).
Report a problemFND-3314054210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

Clinical Trial, Control, Glp-1, Glp-1 Analogue, Glucagon, Glycaemic, Liraglutide

PepBank is a research reference. Talk to a doctor before you use any peptide.